The study of relationship between Immune-related adverse events with immune checkpoint blockade and microbiota change

The study of relationship between Immune-related adverse events with immune checkpoint blockade and microbiota change - The effect of immune checkpoint blockade on microbiota

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000030437

Enrollment

Registered

2018-01-01

Start date

2018-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastric cancer, non-small-cell lung cancer

Interventions

Capsule Endoscopy , Colonoscopy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The man and woman who will underwent chemotherapy using an immune checkpoint blockade for non-small-cell lung cancer, gastric cancer or it was obtained its consent for this study in used one twenty years or older.

Exclusion criteria

Exclusion criteria: The person who was not obtained consent of this study

Design outcomes

Primary

Measure	Time frame
Microbiota in stool were examined using a next-generation high-speed sequencer before underwent chemotherapy and after two rounds of chemotherapy.	—

Countries

Japan

Contacts

Public ContactYuki Hirata

Osaka Medical college Second Department of Internal Medicine

in2145@osaka-med.ac.jp072-683-1221

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026